China (Mainland)
Premiumsupplier
- Product Details
Keywords
- 183319-69-9 factory in China
- Erlotinib hydrochloride factory in China
- 183319-69-9 seller in China
Quick Details
- ProName: Erlotinib hydrochloride
- CasNo: 183319-69-9
- Molecular Formula: C22H24ClN3O4
- Appearance: white powder
- Application: 1. Erlotinib hydrochloride is a kind o...
- DeliveryTime: Within7-10 days after receipt of your ...
- PackAge: As customer request
- Port: Qingdao,China
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99%
- Storage: Store in a cool,dry place and keep awa...
- Transportation: Common products:Sea/Air/Courier ...
- LimitNum: 100 Gram
- MW:: 429.9
- Mol File:: 183319-69-9.mol
- Melting point: 223-225°C
Superiority
Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.
Details
Details
| CAS NO. | 183319-69-9 |
 |
| Erlotinib HCl | ||
| C22H23N3O4.HCl | ||
| 429.9 | ||
| 98% | ||
| can supply large quantity in kgs scale | ||
| Tarceva;CP-358774;CP 358774;CP358774;OSI-774;OSI 774;OSI774;NSC-718781;NSC 718781;NSC718781 | ||
| Erlotinib is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM. | ||
|
Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells. Erlotinib HCl (1 μM) induces apoptosis in DiFi humancolon cancer cells.Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM.Erlotinib HCl(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells.The effects of Erlotinib HCl in combination with gemcitabine are considered additive in KRAS-mutated pancreatic cancer cells. Ten micromolar of Erlotinib HCl inhibits EGFR phospho-rylation at the Y845 (Src-dependent phosphorylation) and Y1068 (auto-phosphorylation) sites. Combination with Erlotinib HCl could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition. |
||
